PMID- 16732759
OWN - NLM
STAT- MEDLINE
DCOM- 20060726
LR  - 20221207
IS  - 1323-1316 (Print)
IS  - 1323-1316 (Linking)
VI  - 60
IP  - 3
DP  - 2006 Jun
TI  - Successful treatment for obsessive-compulsive disorder with addition of low-dose 
      risperidone to fluvoxamine: implications for plasma levels of catecholamine 
      metabolites and serum brain-derived neurotrophic factor levels.
PG  - 389-93
AB  - The authors report on the successful treatment of obsessive-compulsive disorder 
      (OCD) in three patients with the addition of risperidone to ongoing fluvoxamine 
      treatment. Plasma homovanillic acid (HVA), but not 
      3-methoxy-4-hydroxyphenylglycol (MHPG) levels decreased after risperidone 
      administration, and plasma levels of fluvoxamine did not change. In addition, 
      serum brain-derived neurotrophic factor (BDNF) levels were not altered after the 
      recovery from obsessive-compulsive symptoms, indicating that serum BDNF levels 
      might not predict the patient's response to risperidone treatment. Taken 
      together, a combination treatment of risperdone and fluvoxamine might improve 
      obsessive-compulsive symptoms. In short, fluvoxamine enhances the activity of the 
      serotonergic system by inhibiting serotonin transporters, and risperidone 
      decreases that of the dopaminergic system by blocking D2 receptors.
FAU - Yoshimura, Reiji
AU  - Yoshimura R
AD  - Department of Psychiatry, University of Occupational and Environmental Health, 
      Kitakyushu, Fukuoka, Japan. yoshi621@med.uoeh-u.ac.jp
FAU - Kaneko, Sachiko
AU  - Kaneko S
FAU - Shinkai, Koji
AU  - Shinkai K
FAU - Nakamura, Jun
AU  - Nakamura J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Australia
TA  - Psychiatry Clin Neurosci
JT  - Psychiatry and clinical neurosciences
JID - 9513551
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Catecholamines)
RN  - 0 (Serotonin Antagonists)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 534-82-7 (Methoxyhydroxyphenylglycol)
RN  - L6UH7ZF8HC (Risperidone)
RN  - O4L1XPO44W (Fluvoxamine)
RN  - X77S6GMS36 (Homovanillic Acid)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/blood/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Catecholamines/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fluvoxamine/blood/*therapeutic use
MH  - Homovanillic Acid/blood
MH  - Humans
MH  - Male
MH  - Methoxyhydroxyphenylglycol/blood
MH  - Obsessive-Compulsive Disorder/*drug therapy
MH  - Risperidone/blood/*therapeutic use
MH  - Serotonin Antagonists/blood/*therapeutic use
MH  - Selective Serotonin Reuptake Inhibitors/blood/*therapeutic use
EDAT- 2006/05/31 09:00
MHDA- 2006/07/27 09:00
CRDT- 2006/05/31 09:00
PHST- 2006/05/31 09:00 [pubmed]
PHST- 2006/07/27 09:00 [medline]
PHST- 2006/05/31 09:00 [entrez]
AID - PCN [pii]
AID - 10.1111/j.1440-1819.2006.01519.x [doi]
PST - ppublish
SO  - Psychiatry Clin Neurosci. 2006 Jun;60(3):389-93. doi: 
      10.1111/j.1440-1819.2006.01519.x.